By Katherine Hamilton
ScPharmaceuticals shares fell Wednesday morning after it disclosed it might have to delay submitting a new product to the Food and Drug Administration.
Shares were down 8% to $3.25 in recent trading. The stock is down about 61.3% this year.
One lot of the company's SCP-111 combination product showed varying results in shelf-life testing, which is the amount of time a product can maintain an acceptable level of quality, the company said in a Wednesday filing.
SCP-111 is designed to treat fluid overload and retention.
The variation could delay when the company submits a supplemental new drug application for the product with the FDA.
ScPharmaceuticals was planning to submit the product for approval in January, but may delay until later in 2025, the company said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
December 11, 2024 10:24 ET (15:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。